Xvivo Perfusion AB (publ) (FRA:3XV)
21.92
+0.96 (4.58%)
At close: Jan 27, 2026
Xvivo Perfusion AB Revenue
In the year 2025, Xvivo Perfusion AB had annual revenue of 812.17M SEK, down -1.25%. Xvivo Perfusion AB had revenue of 226.14M in the quarter ending December 31, 2025, a decrease of -0.62%.
Revenue
812.17M SEK
Revenue Growth
-1.25%
P/S Ratio
8.97
Revenue / Employee
4.10M SEK
Employees
198
Market Cap
673.35M EUR
Revenue Chart
* This company reports financials in SEK.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 812.17M | -10.25M | -1.25% |
| Dec 31, 2024 | 822.42M | 224.87M | 37.63% |
| Dec 31, 2023 | 597.54M | 182.25M | 43.88% |
| Dec 31, 2022 | 415.29M | 156.91M | 60.73% |
| Dec 31, 2021 | 258.39M | 78.53M | 43.66% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Paul Hartmann AG | 2.44B |
| FRoSTA Aktiengesellschaft | 652.00M |
| Maschinenfabrik Berthold Hermle AG | 469.42M |
| Südwestdeutsche Salzwerke AG | 347.96M |
| EUROKAI GmbH & Co. KGaA | 262.47M |
| Northern Data AG | 200.27M |
| Berliner Effektengesellschaft AG | 174.56M |
| Sedlmayr Grund und Immobilien AG | 139.01M |